The implications are that the therapeutic benefits of IFN treatment are applicable in the early viral phases of COVID-19 and influenza, but that once the pulmonary phases of both infections progress to hyper-inflammation, IFN treatment is likely to be contra-indicated. This evidence concerns the gene IFNA1 and infection.